August 2010
|
-
Long-Term Therapy with Tenofovir is Effective for
Patients Co-Infected with HIV and HBV.
de Vries-Sluijs TE, Reijnders JG, Hansen BE, et alGastroenterology.
2010 Aug 26.
-
Tenofovir nephrotoxicity: acute tubular necrosis with
distinctive clinical, pathological, and
mitochondrial abnormalities.
Herlitz LC, Mohan S, Stokes MB, et alKidney Int.
2010 Sep 1
-
Different Evolution of Genotypic Resistance
Profiles to Emtricitabine Versus Lamivudine in
Tenofovir-Containing Regimens.
Svicher V, Alteri C, Artese A,
et al J Acquir Immune Defic Syndr.
2010 Aug 24
-
Systematic review and meta-analysis: renal safety of tenofovir
disoproxil fumarate in
HIV-infected patients.
Cooper RD, Wiebe N, Smith N, et al
Clin Infect Dis.
2010 Sep 1;51(5):496-505.
-
Tolerability of HIV postexposure prophylaxis with
tenofovir/emtricitabine and lopinavir/ritonavir
tablet formulation.
Tosini W, Muller P, Prazuck T, et al
AIDS. 2010 Aug 19
-
Tenofovir-linked hyperparathyroidism is independently associated
with the presence
of vitamin D deficiency.
Rosenvinge MM, Gedela K, Copas AJ, et al
J Acquir Immune Defic Syndr.
2010 Aug 15;54(5):496-9.
-
Short communication: inadequate vitamin d exacerbates parathyroid
hormone
elevations in tenofovir users.
Childs KE, Fishman SL, Constable C, et al
AIDS Res Hum Retroviruses.
2010 Aug;26(8):855-9.
|
July 2010
XVIII IAC
Citations
|
- POSTER
Looking beyond TDF based PrEP
K. Fisher, L. Miller, W. Mitchell, et al
PDF Poster
Abstract
- POSTER
Incidence and risk factors for tenofovir-associated renal function
decline among Thai HIV-infected
patients with low-body weight
K. Chaisiri, C. Bowonwatanuwong, P. Visuttimak, et al
PDF Poster
Abstract
- POSTER
Recruitment challenges and strategies in the phase II extended
safety trial of tenofovir (TDF) HIV
chemoprophylaxis in three US cities among men who have sex with
men (MSM)
L. Grohskopf, C. Alinsung, S. Buchbinder, et al
PDF Poster
Abstract
- POSTER
The partners PrEP study: enrollment of HIV-1 serodiscordant
couples into a phase III, randomized
trial of antiretroviral pre-exposure prophylaxis for HIV-1
prevention
J. Baeten, N. Mugo, P. Ndase, et al
PDF Poster
Abstract
-
Preliminary analysis of biomedical data from the phase II clinical
safety trial of tenofovir disoproxil
fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among
U.S. men who have sex with men
(MSM)
L. Grohskopf, R. Gvetadze, S. Pathak, et al
-
Enrollment and follow-up of injecting drug users in an HIV
pre-exposure prophylaxis trial in Bangkok
K. Choopanya, S. Vanichseni, P. Suntharasamai, et al
-
Safety
and efficacy of switch from AZT or d4T to ABC or TNF. 96 weeks
data from observational cohort: POLCA 002 study
E. Bakowska, J. Kubicka, Z. Lewandowski, et al
-
TDF-3TC-NVP is inferior to AZT-3TC-NVP in a large ART program in
Nigeria
K. Scarsi, K. Darin, H. Rawizza, et al
-
Use of
tenofovir in a cohort of HIV-infected pregnant women and their
infants
R. Rosso, A. Di Biagio, C. Gotta, et al
-
Safety
of tenofovir use during pregnancy: associations with low birth
weight and early growth in
HIV-exposed uninfected infants
G. Siberry, P. Williams, H. Mendez, et al
-
Tenofovir prevention trials need more scrutiny
R. Ramanathan
-
Saying
'no' to clinical research: Malawi's denial to study tenofovir PrEP
E. Chigwedere, M. Mkunthi, M. Ukpong, et al
-
Do
systemic and genital tract tenofovir concentrations predict HIV
seroconversion in the
CAPRISA 004 tenofovir gel trial?
A.D. Kashuba, S.S. Abdool Karim, E. Kraft, et al
-
Safety
of 1% tenofovir vaginal microbicide gel in South African women:
results of the CAPRISA 004 trial
D. Sokal, Q. Karim, Z. Omar, et al
-
Antiretroviral regimen and pharmacogenetic determinants of
tenofovir-associated change in creatinine
clearance in ACTG protocol A5142
M. Goicoechea, Y. Zheng, M. Hughes, et al
-
Neither
abacavir nor tenofovir induce direct in vitro effects on
endothelial cells
C. Kim, G. Rajashekhar, S. Gupta, et al
-
Evaluation of renal insufficiency caused by the nucleotide reverse
transcriptase inhibitor tenofovir in
HIV-infected patients from 2001 to 2009 followed at the center for
comprehensive care, St Luke´s
Roosevelt Hospital Center, New York, USA
G. Nadkarni, A Briasoulis, M. Bhatti, et al
-
Economic
evaluation of tenofovir disoproxil fumarate and zidovudine in
first-line HIV antiretroviral
treatment in South Africa
C. Marais, R. Shaw, F. Conradie, et al
-
Challenging pharmaceutical patent strategies to improve access to
ARVs in Brazil: the case
of
tenofovir
F. Viegas Neves da Silva, R. Reis, M. Fogaça Vieira, et al
|
Journal
Citations
|
|
-
A WEEK-IN-REVIEW FEATURED REPORT
Systematic Review and Meta-analysis: Renal Safety of Tenofovir
Disoproxil Fumarate in
HIV-Infected Patients.
Cooper RD, Wiebe N, Smith N,
et al
Clin Infect Dis.
2010 Jul 13
-
A WEEK-IN-REVIEW FEATURED REPORT
A pilot study to determine the impact on dyslipidemia of adding
tenofovir to stable
background antiretroviral therapy: ACTG 5206.
Tungsiripat M, Kitch D, Glesby MJ, et al
AIDS.
2010 Jul 17;24(11):1781-4.
-
A WEEK-IN-REVIEW FEATURED REPORT
A pilot study to determine the impact on dyslipidemia of adding
tenofovir to stable
background antiretroviral therapy: ACTG 5206.
Tungsiripat M, Kitch D, Glesby MJ, et al
AIDS.
2010 Jul 17;24(11):1781-4.
-
Effectiveness and Safety of Tenofovir Gel, an
Antiretroviral Microbicide, for the
Prevention of HIV Infection in Women.
Karim QA, Karim SS, Frohlich JA, et al
Science.
2010 Jul 19
-
Lower arterial stiffness and Framingham score after
switching abacavir to tenofovir in men
at high cardiovascular risk.
Sinn K, Richardson R, Carr A.
AIDS.
2010 Jul 19
-
Renal toxicity associated with tenofovir use.
Rodriguez-Nóvoa S, Alvarez E, Labarga P, Soriano V.
Expert Opin Drug Saf.
2010 Jul;9(4):545-59
|
|
|
|
|
|
|
|
|
|
Prescribing
Information
Guidelines